See more : Lixte Biotechnology Holdings, Inc. (LIXTW) Income Statement Analysis – Financial Results
Complete financial analysis of Ildong Pharmaceutical Co., Ltd. (249420.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ildong Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- TOWA Hi SYSTEM CO.,LTD. (4172.T) Income Statement Analysis – Financial Results
- Petro River Oil Corp. (PTRC) Income Statement Analysis – Financial Results
- Nations Technologies Inc. (300077.SZ) Income Statement Analysis – Financial Results
- ioneer Ltd (INR.AX) Income Statement Analysis – Financial Results
- Nippon Signal Co., Ltd. (6741.T) Income Statement Analysis – Financial Results
Ildong Pharmaceutical Co., Ltd. (249420.KS)
About Ildong Pharmaceutical Co., Ltd.
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 600.76B | 637.71B | 560.13B | 561.85B | 517.47B | 503.91B | 460.65B | 201.34B |
| Cost of Revenue | 393.22B | 401.37B | 340.69B | 323.43B | 285.11B | 248.75B | 234.42B | 104.05B |
| Gross Profit | 207.54B | 236.34B | 219.44B | 238.41B | 232.36B | 255.16B | 226.23B | 97.30B |
| Gross Profit Ratio | 34.55% | 37.06% | 39.18% | 42.43% | 44.90% | 50.64% | 49.11% | 48.32% |
| Research & Development | 95.02B | 109.90B | 96.52B | 60.18B | 48.50B | 46.46B | 33.36B | 12.51B |
| General & Administrative | 13.39B | 13.97B | 12.41B | 11.57B | 15.05B | 17.21B | 17.18B | 6.35B |
| Selling & Marketing | 68.86B | 101.10B | 82.97B | 84.96B | 87.81B | 80.02B | 73.76B | 28.93B |
| SG&A | 165.94B | 115.07B | 95.38B | 96.53B | 102.86B | 97.23B | 90.94B | 35.28B |
| Other Expenses | 1.91B | 84.71B | 81.91B | 75.07B | 82.37B | 1.48B | 1.04B | 898.46M |
| Operating Expenses | 260.96B | 309.68B | 273.82B | 231.78B | 233.73B | 226.81B | 200.87B | 82.50B |
| Cost & Expenses | 654.18B | 711.05B | 614.51B | 555.21B | 518.84B | 475.56B | 435.29B | 186.55B |
| Interest Income | 1.09B | 1.55B | 569.37M | 260.18M | 342.64M | 408.48M | 254.28M | 59.23M |
| Interest Expense | 14.72B | 9.79B | 10.56B | 4.67B | 5.23B | 3.59B | 3.75B | 1.72B |
| Depreciation & Amortization | 28.32B | 29.54B | 29.31B | 27.66B | 27.92B | 23.60B | 18.45B | 7.50B |
| EBITDA | -51.23B | -80.49B | -101.34B | 22.61B | 10.51B | 50.75B | 43.81B | 23.24B |
| EBITDA Ratio | -8.53% | -6.83% | -4.22% | 6.36% | 5.15% | 10.70% | 9.76% | 11.54% |
| Operating Income | -53.42B | -73.33B | -54.38B | 6.63B | -1.26B | 28.34B | 25.36B | 14.79B |
| Operating Income Ratio | -8.89% | -11.50% | -9.71% | 1.18% | -0.24% | 5.62% | 5.51% | 7.35% |
| Total Other Income/Expenses | -40.86B | -46.34B | -86.83B | -16.36B | -21.26B | -11.91B | -4.94B | -778.13M |
| Income Before Tax | -94.27B | -119.82B | -141.21B | -9.72B | -22.63B | 16.44B | 20.42B | 14.01B |
| Income Before Tax Ratio | -15.69% | -18.79% | -25.21% | -1.73% | -4.37% | 3.26% | 4.43% | 6.96% |
| Income Tax Expense | -13.31B | 22.35B | -40.24B | 3.30B | -9.19B | 3.72B | 580.89M | 1.44B |
| Net Income | -78.93B | -142.17B | -100.97B | -13.02B | -13.44B | 12.72B | 19.84B | 12.58B |
| Net Income Ratio | -13.14% | -22.29% | -18.03% | -2.32% | -2.60% | 2.52% | 4.31% | 6.25% |
| EPS | -2.92K | -5.40K | -4.24K | -547.34 | -565.08 | 534.63 | 876.19 | 610.39 |
| EPS Diluted | -2.92K | -5.40K | -4.24K | -547.34 | -565.08 | 534.29 | 876.19 | 610.39 |
| Weighted Avg Shares Out | 27.03M | 26.34M | 23.79M | 23.79M | 23.79M | 23.79M | 22.64M | 20.61M |
| Weighted Avg Shares Out (Dil) | 27.03M | 26.34M | 23.79M | 23.79M | 23.79M | 23.81M | 22.64M | 20.61M |
Source: https://incomestatements.info
Category: Stock Reports